2014
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
Wang W, Liu L, Xu H, Sun H, Wu C, Zhu X, Zhang W, Xu J, Liu C, Long J, Ni Q, Tang Z, Yu X. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget 2014, 5: 3895-3906. PMID: 25008315, PMCID: PMC4116529, DOI: 10.18632/oncotarget.2019.Peer-Reviewed Original ResearchConceptsSurvival of hepatocellular carcinomaMicrovessel densityHepatocellular carcinomaSorafenib treatmentDissemination of hepatocellular carcinomaAssociated with inhibition of angiogenesisAdvanced hepatocellular carcinomaMicrovessel density valuesCurative HCC resectionSuppressor of tumor growthInhibition of angiogenesisNegative prognostic indicatorAssociated with inhibitionSorafenib interventionHCC resectionSorafenib administrationOverall survivalDisease recurrencePrognostic factorsTissue microarrayPrognostic indicatorTumor growthSorafenibPersonalized treatmentPredictive value
2012
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
Zhao X, Tian C, Puszyk W, Ogunwobi O, Cao M, Wang T, Cabrera R, Nelson D, Liu C. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Laboratory Investigation 2012, 93: 8-19. PMID: 23108376, PMCID: PMC3860369, DOI: 10.1038/labinvest.2012.144.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCarcinoma, HepatocellularCell Line, TumorCytochromes cDown-RegulationGene Knockdown TechniquesGTP PhosphohydrolasesHumansLiverLiver NeoplasmsMiceMice, SCIDMitochondriaNiacinamidePhenylurea CompoundsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRaf KinasesRas ProteinsRNA, Small InterferingSignal TransductionSorafenibXenograft Model Antitumor AssaysConceptsHepatocellular carcinomaSorafenib-induced apoptosisHCC xenograft tumor growthOptic atrophy 1HCC cellsPatients' hepatocellular carcinomaNon-tumor tissue samplesAdvanced hepatocellular carcinomaPathogenesis of HCCNovel therapeutic targetTumorigenesis of HCCXenograft tumor growthTumor tissue analysisNormal human primary hepatocytesHuman primary hepatocytesCell growth inhibitionSorafenib treatmentHCC patientsTherapeutic targetExposure of cellsTumor growthMitochondrial injuryPatientsSorafenibOPA1 expression